Incyte presents final results from a Phase I trial of INCB024360 Incyte presented final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 IDO1, inhibitor, INCB024360, at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. IDO1 inhibition may provide a new approach in enhancing the immune system in patients with a variety of solid tumors. Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies. Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.